Product image of Glycophos (Sodium Glycerophosphate Pentahydrate) supplied by GNH India

Glycophos

Active Ingredient:
Sodium Glycerophosphate Pentahydrate
Origin:
EU

Glycophos (Sodium Glycerophosphate Pentahydrate)

Glycophos is a prescription intravenous solution containing the active ingredient sodium glycerophosphate pentahydrate. The product’s strength is not specified in the available data, and it is marketed within the European Union. As a phosphate supplement, Glycophos is administered by healthcare professionals to address conditions associated with low serum phosphate levels.

Manufacturer / TM Owner

Fresenius Kabi Ab

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Glycophos is indicated for the treatment of phosphate depletion and related metabolic disturbances. It is used in clinical settings where rapid restoration of serum phosphate is required.

  • Management of hypophosphatemia in hospitalized patients
  • Support during prolonged parenteral nutrition
  • Correction of phosphate loss after major surgery or trauma
  • Adjunct therapy in patients receiving continuous renal replacement therapy
  • Treatment of phosphate deficiency associated with refeeding syndrome

Side Effects

Side effects of Glycophos may vary in frequency and severity. Patients should be monitored for any adverse reactions during and after infusion.

Common

  • Mild local irritation at the infusion site
  • Transient hyperphosphatemia
  • Nausea or vomiting
  • Headache
  • Flushing or warmth sensation

Serious

  • Severe hyperphosphatemia leading to calcium-phosphate precipitation
  • Allergic reactions such as rash, itching, or anaphylaxis
  • Hypotension due to rapid infusion
  • Metabolic acidosis in susceptible individuals

Precautions & Warnings

When using Glycophos, clinicians should consider several safety factors to minimize risks.

  • Assess baseline serum phosphate, calcium, and renal function before administration
  • Adjust dose in patients with renal impairment or severe hyperphosphatemia
  • Infuse at the recommended rate to avoid rapid shifts in phosphate levels
  • Monitor electrolytes and acid‑base status during therapy
  • Use caution in patients with a history of hypersensitivity to phosphate preparations
  • Discontinue if signs of severe hyperphosphatemia or allergic reaction develop

Avoid Interactions

Glycophos may interact with other medications or clinical conditions. Awareness of these interactions helps guide safe use.

Avoid

  • Concurrent administration of calcium-containing solutions that may precipitate with phosphate
  • High-dose vitamin D analogues that increase calcium absorption, raising risk of calcium‑phosphate precipitation

Use with caution

  • Loop diuretics, which can affect electrolyte balance
  • Antacids containing aluminum or magnesium, which may alter phosphate absorption
  • Blood transfusions, as citrate may bind calcium and affect phosphate dynamics
  • Medications that affect renal function, such as aminoglycosides or NSAIDs

Frequently Asked Questions

Glycophos contains sodium glycerophosphate pentahydrate as its active pharmaceutical ingredient.

Glycophos is supplied as an intravenous solution and is administered by a healthcare professional through a vein.

Glycophos is used to treat hypophosphatemia and other forms of phosphate depletion, often in hospitalized patients.

Patients with renal impairment require careful monitoring and possible dose adjustment when receiving Glycophos.

Common side effects include mild local irritation at the infusion site, transient hyperphosphatemia, nausea, headache, and flushing.

Serious reactions may include severe hyperphosphatemia with calcium‑phosphate precipitation, allergic reactions such as anaphylaxis, hypotension, and metabolic acidosis.

Calcium-containing solutions should be avoided concurrently because they can precipitate with phosphate, leading to complications.

No, Glycophos is a prescription‑only medication and must be prescribed by a qualified healthcare provider.

Serum phosphate, calcium, renal function, and acid‑base status should be monitored before and during treatment.

Yes, Glycophos can be used to supplement phosphate in patients receiving prolonged parenteral nutrition.

Glycophos is classified under ATC code B05XA02, which denotes phosphate supplements.

Patients should follow medical advice regarding calcium and vitamin D intake, as excessive amounts may affect phosphate balance.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sodium Glycerophosphate Pentahydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT